Results 11 to 20 of about 121,885 (262)
Head and neck squamous cell carcinoma [PDF]
Nature Reviews Disease Primers, 2020 Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection ...
Johnson, Daniel E +5 more
+10 more sources
Cutaneous Squamous Cell Carcinoma of the Head and Neck [PDF]
Journal of Skin Cancer, 2011 Cutaneous squamous cell carcinoma of the head and neck is an epidemic that reaches all parts of the world. Making the diagnosis relies on the acumen of the clinician and pathologist. Various pathologic subtypes exist and differ in histology and prognosis.
Vivek V. Gurudutt, Eric M. Genden
openaire +3 more sources
Immunotherapy for Head and Neck Squamous Cell Carcinoma [PDF]
Current Oncology Reports, 2018 Discussion of current strategies targeting the immune system related to solid tumors with emphasis on head and neck squamous cell carcinoma (HNSCC).This review will outline the current challenges with immunotherapy and future goals for treatment using these agents.Agents targeting immune checkpoint receptors (IR) such as program death 1 (PD1) have been
Moskovitz, Jessica +2 more
openaire +2 more sources
Immunotherapy for Head and Neck Squamous Cell Carcinoma [PDF]
Current Oral Health Reports, 2016 Head and neck squamous cell carcinoma has been found to be an immunosuppressive malignancy, with many defects in the host immune system contributing to the progression of disease. A greater understanding of these defects has lead to the identification and investigation of new therapeutic strategies, targeting immune system dysfunction in an effort to ...
Rebecca C, Hoesli, Jeffrey S, Moyer
openaire +5 more sources
Immunotherapy for Head and Neck Squamous Cell Carcinoma [PDF]
Hematology/Oncology Clinics of North America, 2015 Although head and neck squamous cell carcinoma has traditionally been considered to be a very immunosuppressive, or at least nonimmunogenic, tumor type, recent results from clinical studies of immune checkpoint blockade strategies have led to resurgence in the enthusiasm for immunotherapeutic approaches. Additional strategies for immunotherapy that are
David W, Schoppy, John B, Sunwoo
openaire +4 more sources
Squamous cell carcinoma of the head and neck in the elderly [PDF]
Reports of Practical Oncology & Radiotherapy, 2013 The incidence of head and neck squamous cell carcinoma (HNSCC) peaks between the fifth and seventh decades of life. With prolongation of life expectancy, however, the proportion of elderly HNSCC patients is also increasing, which makes HNSCC in this life period an important issue for healthcare providers.
Gugić, Jasenka, Strojan, Primož
openaire +2 more sources
Exosomes in Head and Neck Squamous Cell Carcinoma [PDF]
Frontiers in Oncology, 2019 Exosomes are small membranous vesicles that contain proteins, lipids, genetic material, and metabolites with abundant information from parental cells. Exosomes carry and deliver bioactive contents that can reprogram the functions of recipient cells and modulate the tumor microenvironment to induce pathological events through cell-to-cell communication ...
Cheng Xiao +5 more
openaire +3 more sources
Hypoxia in Head and Neck Squamous Cell Carcinoma [PDF]
ISRN Otolaryngology, 2012 Hypoxia is a common feature in most of the solid tumors including head and neck squamous cell carcinoma (HNSCC). Hypoxia reflects the imbalance between oxygen consumption by the rapidly proliferating cancer cells and the insufficient oxygen delivery due to poor vascularization and blood supply.
John Zenghong Li +4 more
openaire +2 more sources
Immunotherapy for squamous cell carcinoma of the head and neck [PDF]
Japanese Journal of Clinical Oncology, 2020 Abstract Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell ...
Tomoya Yokota +19 more
openaire +2 more sources
Cetuximab in squamous cell head and neck carcinomas
Annals of Oncology, 2007 The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration.
GEBBIA, Vittorio +5 more
openaire +3 more sources